Clinical trial
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced…
NCT00428766 · Morphotek, Industry · Completed
Key facts
| NCT number | NCT00428766 |
|---|---|
| Title | Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer |
| Official title | A Study of the Safety, Tolerability, and Pharamcokinetics of MORAb-003, a Humanized Monoclonal Antibody, in Subjects With Advanced Ovarian Cancer |
| Lead sponsor | Morphotek, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian Cancer |
| Intervention type | Drug |
| Interventions | MORAb-003 |
| Enrollment | 24 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jan 30, 2007 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: